2007 Fiscal Year Final Research Report Summary
Development of new system to predict clinical outcome of anti-cancer agent using peripheral lymphocyte
| Project/Area Number |
18591481
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
ICHIKAWA Wataru Saitama Medical University, Medicine, Associate professor (70282738)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Keywords | DNA array / fluoronyrimidine / gene expression |
|---|
| Research Abstract |
The aim of this study consists of two portion; 1) identification of candidate gene expressions in peripheral lymphocyte to predict the clinical outcome, and 2) development of focused DNA▲array system including these candidate genes.
1) We successfully identified 12 genes and 29 genes to correlate with the efficacy and the adverse event, respectively, in fluoropyrimidine-based chemotherapy.
2) We made the probes for specific targeted DNA to obtain high specificity, and prepared the spotting dose of the targeted DNA for high sensitivity, for these 41 genes.
3)The pathway analysis revealed the importance of ERCC6 and BUB3 to predict the clinical outcome in fluoropyrimidine chemotherapy.
4) However, we could not predict the clinical outcome in the validation. set because of unexpected low specificity of probes and low sensitivity of probes.
Thus, further studies will be necessary to improve the specificity and sensitivity of this focused DNA array system.
|
-
-
-
-
[Journal Article] CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-12008
Author(s)
Fujita, K, Yamamoto, W, Endo, S, Endo, H, Nagashima, F, Ichikawa, W, et. al.
-
Journal Title
Cancer Sci 99(5)
Pages: 1049-54
Description
「研究成果報告書概要(欧文)」より
-
-
-
